Draft monograph: Cagrilintide — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. Adverse event frequencies are given without the denominator or the exposure period — arising from DRAFT-CAGRILINTIDE/001. Every reported frequency now carries the number of participants, the number of events and the exposure period, and comparator-arm figures are reported alongside rather than in a separate table.
2. What happens to weight after the compound is stopped is not in the assessed outcomes — arising from DRAFT-CAGRILINTIDE/002. Post-withdrawal trajectory is now an assessed outcome wherever a withdrawal period was studied, rated on the same scale as the others. Where no withdrawal period was studied the outcome is recorded as not assessed.
3. Point estimates are given without an interval — arising from DRAFT-CAGRILINTIDE/003. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
4. The absence of a rare harm in the trial set is presented as reassurance — arising from DRAFT-CAGRILINTIDE/004. Wherever the monograph reports that an event was not observed, it now states the total exposure and the frequency the contributing trials could have detected, so that the absence is read as the limit of the evidence rather than as a finding.
5. The compound is supplied under names the monograph does not list — arising from DRAFT-CAGRILINTIDE/005. The synonym list is extended to include every name the Institute can evidence from a document it holds, each recorded with its source. Names asserted without a supporting document are not added, and the distinction is stated at the head of the list.
6. The monograph does not tell a reader that two vials of the same compound may not contain the same… — arising from DRAFT-CAGRILINTIDE/006. A standing paragraph now appears at the head of §8 in every monograph, stating that a determination applies to the lot measured and that a label mass is not a determination.
7. Trials are described as terminated where they completed as planned — arising from DRAFT-CAGRILINTIDE/007. Trial status now uses a fixed vocabulary defined in the glossary, and where the reason for stopping is not evidenced by a document the Institute holds, the status is recorded as stopped with the reason not established rather than assigned.
8. The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-CAGRILINTIDE/009. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
9. References should carry a persistent identifier for every cited source — arising from DRAFT-CAGRILINTIDE/010. Every reference without a persistent identifier now carries an explicit statement that the identifier is not held by the Institute, so that its absence is a recorded fact rather than an apparent oversight.
10. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-CAGRILINTIDE/011. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
11. A near-isobaric analogue is not distinguished by the identity determination described — arising from DRAFT-CAGRILINTIDE/012. The analytical section now states the resolving power required to discriminate the pair, names the pair explicitly, and records that an identity claim made below that resolution is not conformant with the identity standard.
12. Anti-drug antibody data are omitted — arising from DRAFT-CAGRILINTIDE/013. Anti-drug antibody incidence and any reported association with loss of effect are now reported where measured, and recorded as not measured where the contributing trials did not assess them.
13. Regulatory status is stated without naming the jurisdiction — arising from DRAFT-CAGRILINTIDE/014. Every regulatory status statement now names the authority, states the date on which the status was verified, and is recorded per jurisdiction rather than as a single global assertion.
14. The route of administration studied is not the route in which the compound is supplied — arising from DRAFT-CAGRILINTIDE/015. The assessed-outcome table now carries the studied route in every row, and a standing note appears wherever the supplied presentation differs from it.
15. Nothing is said about impaired renal or hepatic clearance — arising from DRAFT-CAGRILINTIDE/016. The pharmacokinetic table now carries renal and hepatic rows in every monograph, populated with the study where one exists and with an explicit statement of absence where none does.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.